STP-938 is under clinical development by Step Pharma and currently in Phase II for Diffuse Large B-Cell Lymphoma. According to GlobalData, Phase II drugs for Diffuse Large B-Cell Lymphoma have a 40% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how STP-938’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
STP-938 overview
STP-938 is under development for the treatment of autoimmune disorder such as rheumatoid arthritis, inflammation, solid tumors, multiple myeloma and hematological malignancies such as b-cell lymphoma including mantle cell lymphoma, diffuse large b-cell lymphoma, peripheral t-cell lymphomas, marginal zone b-cell lymphoma, follicular lymphoma and cutaneous t-cell lymphoma and mantle cell lymphoma. The drug candidate is administered through the oral route. The drug candidate acts by targeting CTP synthase 1 (cytidine triphosphate synthase).
See Also:
Step Pharma overview
Step Pharma is a pharmaceutical company that discovers and develops novel therapeutics. The company develops a new class of oral nucleotide synthesis inhibitors against cytidine triphosphate synthase 1 (CTPS1) inhibitors. Its candidate is STP938, a small molecule inhibitor of CTPS1 currently in non-clinical development. Step Pharma’s product is used in the therapeutic areas T cell lymphomas, B-cell lymphomas, solid tumors, autoimmune diseases and others. The company collaborates with academic laboratories, clinical centers, and biopharmaceutical industry leaders to commercialize its programs and products. It operates across France. Step Pharma is headquartered in Saint-Genis-Pouilly, Pays-de-la-Loire, France.
For a complete picture of STP-938’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
